<DOC>
	<DOCNO>NCT01275131</DOCNO>
	<brief_summary>The purpose study determine recombinant human hyaluronidase PH20 ( rHuPH20 ) change exposure action approve insulin analog give continuous subcutaneous insulin infusion ( CSII ) participant Type 1 diabetes mellitus ( T1DM ) . This study divide Stage 1 , 2 , 3 . Stage 3 start chronologically Stage 2 , prior perform Stage 2 , Sponsor make decision terminate Stage 2 . Stage 2 initiate due strategic business decision termination base safety efficacy concern . No participant enrol Stage 2 .</brief_summary>
	<brief_title>Randomized , Double-blind , Crossover , Pharmacokinetic ( PK ) Glucodynamic ( GD ) Study Continuous Subcutaneous Insulin Infusion ( CSII ) Participants With Type 1 Diabetes Mellitus ( T1DM )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>1 . Male female age 18 65 year , inclusive . Females childbearing potential must use standard effective mean birth control duration study . 2 . Nonsmoking participant Type 1 diabetes mellitus ( T1DM ) treat insulin great equal 12 month . Nonsmoking mean abstinence cigarettes cigar 3 month negative cotinine screening test . 3 . Body mass index ( BMI ) 18.0 35.0 kilogram per meter square ( kg/m^2 ) , inclusive . 4 . Glycosylated hemoglobin A1c ( HbA1c ) â‰¤10 % base local laboratory result . 5 . Fasting Cpeptide &lt; 0.6 nanogram per milliliter ( ng/mL ) . 6 . Current treatment insulin &lt; 90 unit per day ( U/d ) . 7 . Routine use continuous subcutaneous insulin infusion ( CSII ) primary route insulin administration . 8 . Participant good general health base medical history physical examination , without medical condition might prevent completion study drug infusion assessment require protocol . 1 . Known suspected allergy component study drug trial . 2 . Previous enrollment trial ( Exception : participant Stage 1 permitted participate Stage 2 ) . 3 . Use drug may interfere interpretation trial result know cause clinically relevant interference insulin action , glucose utilization , recovery hypoglycemia . Participants take maintenance dos blood thinner ( eg , Coumadin heparin ) exclude . 4 . Use longacting insulin injection within 72 hour Stage 1 Stage 3 . 5 . Recurrent major hypoglycemia hypoglycemic unawareness , judge Investigator . 6 . Current addiction alcohol substance abuse determine Investigator . 7 . Blood donation phlebotomy ( &gt; 500 milliliter [ mL ] ) within previous 8 week Screening . This apply new participant participant participate Stage 1 wish continue Stage 2 . 8 . Pregnancy , breastfeeding , intention become pregnant , use adequate contraceptive measure ( adequate contraceptive measure consist sterilization , intrauterine device [ IUD ] , oral injectable contraceptive , barrier method ) . 9 . Symptomatic gastroparesis . 10 . Receipt investigational drug within 4 week Stage 1 Stage 2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Insulin analog</keyword>
	<keyword>Type 1 diabetes mellitus</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Glucodynamic</keyword>
	<keyword>Phase 1</keyword>
</DOC>